Skip to main content
OpenTrials
Completed

NCT Number: NCT01382212

A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated for secondary hyperparathyroidism. Subjects will be in the dosing period of the study for 12 weeks in order to evaluate the incidence of hypercalcemia (high calcium levels in blood). Approximately 12 subjects will be enrolled and all 12 will receive paricalcitol capsules.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

End-stage Renal Disease Chronic Disease Disease Attributes Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hyperparathyroidism Hyperparathyroidism, Secondary Kidney Diseases Kidney Failure, Chronic Male Urogenital Diseases Parathyroid Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Secondary Hyperparathyroidism Urogenital Diseases Urologic Diseases

Age range

10 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject must be receiving peritoneal dialysis or hemodialysis for at least 3 months prior to Screening
  • Subject is currently being diagnosed and/or treated for secondary hyperparathyroidism
  • For entry into the Dosing Period (for subjects that are naïve to Vitamin D Receptor [VDR] Activators or those who have completed a 2 to 12 week washout), the subject must meet the following laboratory criteria prior to enrollment:
  • A corrected calcium value ≥ 8.2 and ≤ 10.4 mg/dL
  • A phosphorus value ≤ 6.5 mg/dL
  • An intact parathyroid hormone (iPTH) value > 300 pg/mL and less ≤ 2000 pg/mL

Exclusion criteria

  • Subject is expected or scheduled to receive a living donor kidney transplant within 3 months of Screening or is a kidney transplant patient requiring full immunosuppressant therapy
  • Subject is expected to stop peritoneal dialysis or hemodialysis within 4 months of Screening (per investigator discretion)
  • Subject has had a parathyroidectomy within 12 weeks prior to Screening
  • Subject has had symptomatic or significant hypocalcemia requiring VDR Activator therapy (i.e., calcitriol, paricalcitol, or doxercalciferol) within 2 months prior to Screening
  • Subject is taking maintenance calcitonin, bisphosphonates, glucocorticoids in an equivalent dose of greater than 5 mg prednisone daily, or other drugs known to affect calcium or bone metabolism within 4 to 8 weeks prior to Dosing
  • Subject is receiving cinacalcet at the time of Screening

Treatment and study plan

Paricalcitol

Drug

Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.

Other names: ABT-358, Zemplar

Primary outcomes

  1. Percentage of Subjects With Hypercalcemia

    Time frame: Day 1 to Week 12

    The percentage of subjects with hypercalcemia, defined as at least 2 consecutive post-baseline corrected calcium values > 10.2 mg/dL (2.55 mmol/L).

Secondary outcomes

  1. Percentage of Subjects With 2 Consecutive Intact Parathyroid Hormone (iPTH)/120 Between 150 and 300 pg/mL

    Time frame: Baseline (last measurement collected prior to the first dose) to Week 12

  2. Percentage of Subjects With 2 Consecutive iPTH Reductions of at Least 30% From Baseline

    Time frame: Baseline (last measurement collected prior to the first dose) to Week 12

  3. Hemoglobin: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  4. Hematocrit: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  5. Red Blood Cells: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  6. White Blood Cells (WBC) and Platelet Count: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  7. Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  8. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactic Dehydrogenase (LDH), and Bone-Specific Alkaline Phosphatase (BSAP): Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

    n=subjects with evaluable Baseline and Post-baseline data for each parameter.

  9. Bilirubin, Blood Urea Nitrogen (BUN), Uric Acid, Magnesium, Glucose, Cholesterol, Triglycerides, High Sensitivity C-Reactive Protein (hsCRP), Inorganic Phosphate, Corrected Calcium, and Creatinine: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

    n=subjects with evaluable Baseline and Post-baseline data for each parameter.

  10. Alkaline Phosphatase: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  11. Sodium, Potassium, Chloride, Bicarbonate: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  12. Total Protein and Albumin: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

    n=subjects with evaluable Baseline and Post-baseline data for each parameter.

  13. Fibroblast Growth Factor-23 (FGF-23), 1,25-Hydroxy Vitamin D, 25-Hydroxy Vitamin D, and Intact Parathyroid Hormone (iPTH): Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

    n=subjects with evaluable Baseline and Post-baseline data for each parameter.

  14. Osteocalcin: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  15. Number of Subjects With Adverse Events

    Time frame: From first dose of study drug until 30 days following last dose of study drug (up to 16 weeks).

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.

  16. Number of Subjects With Potentially Clinically Significant Electrocardiogram (ECG) Findings

    Time frame: Baseline (Day 1) to Final Visit (up to Week 12)

    12-lead ECGs were recorded after the subject had been in the supine position for at least 5 minutes. The number of subjects with potentially clinically significant ECG findings, as determined by the investigator, is presented.

  17. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

    Blood pressure was measured after the subject had been sitting for at least 3 minutes.

  18. Heart Rate: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

    Heart rate was measured after the subject had been sitting for at least 3 minutes.

  19. Oral Body Temperature: Mean Change From Baseline to Final Visit

    Time frame: Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)

  20. Number of Subjects With Potentially Clinically Significant Physical Examination Findings

    Time frame: Baseline (Day 1) and Final Visit (up to Week 12)

Sponsors and collaborators

Lead sponsor

AbbVie (prior sponsor, Abbott)

Industry

Registry information

Official study title

A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Jun 27, 2011
Registry last updated
Jul 2, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.